

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobivac Ducat lyophilisate and solvent for suspension for injection, for cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose (1 ml) of reconstituted vaccine contains:

Active substances:

Live attenuated feline calicivirus, strain F9: $\geq 10^{4.6}$ PFU².

Live attenuated feline rhinotracheitis virus, strain G2620A: $\geq 10^{4.8}$ TCID₅₀¹;

¹TCID₅₀: Tissue Culture Infectious Dose 50%

²PFU: Plaque-Forming Units

Excipients:

Qualitative composition of excipients and other constituents
<u>Lyophilisate:</u>
Disodium phosphate dihydrate
Hydrolysed gelatin
Sucrose
<u>Solvent:</u>
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections

Lyophilisate: off-white pellet.

Solvent: clear colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Cats.

3.2 Indications for use for each target species

Active immunisation of cats to reduce the clinical signs caused by infection with feline rhinotracheitis virus (FVR) and feline calicivirus infections (FCV).

Onset of immunity: 4 weeks.

Duration of immunity: 1 year.

3.3 Contraindications

See section 3.7.

3.4 Special warnings

Vaccination at six weeks of age has been proven to be safe.

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Care should be taken that aerosol is not formed when vaccinating the cat as nasal or oral exposure could result in clinical respiratory signs including lethargy and malaise. For the same reason, the cat should be prevented from licking the injection site.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cats:

Very common (>1 animal / 10 animals treated):	Injection site swelling. ¹
Common (1 to 10 animals / 100 animals treated):	Elevated temperature. ²
Rare (1 to 10 animals / 10,000 animals treated):	Hypersensitivity reactions (e.g. pruritus, dyspnoea, vomiting, diarrhoea and collapse including anaphylaxis). ³ Lethargy. ⁴
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site pain. ¹ Febrile limping syndrome reactions in kittens. ⁵

¹ A local swelling (≤ 5 mm), sometimes painful, may be observed at the injection site for one day post-vaccination.

² Elevated body temperature (up to 40 °C) may occur for 1-2 days post vaccination.

³ Sometimes fatal. If such a reaction occurs, appropriate treatment should be administered without delay.

⁴ Lethargy may be observed during the first day after vaccination.

⁵ As reported in the literature, febrile limping syndrome reactions in kittens may occur after the use of any vaccine containing a feline calicivirus component.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See section “Contact details” of the package leaflet.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Do not use during pregnancy and lactation as the product has not been tested in pregnant and lactating queens.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy from the concurrent use of this vaccine with any other, except the vaccine in the Nobivac range containing rabies antigen, strain Pasteur RIV, where this product and the combined use is authorised. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Allow the sterile solvent provided to reach room temperature. Aseptically reconstitute the lyophilised vaccine with one ml of the solvent. Shake well after addition of the solvent. One ml of the reconstituted vaccine should be given by subcutaneous injection.

Visual appearance of the reconstituted product: off-pink or pink coloured suspension.

Vaccination schedule:

Primary vaccination:

Cats from 8 weeks of age onwards should receive two vaccinations with an interval of 3-4 weeks.

Revaccination:

Annual booster.

During the initial vaccination course, the vaccine in the Nobivac range containing rabies antigen, strain Pasteur RIV, may be used to reconstitute this vaccine at the vaccination at 12 weeks of age (where this product and the combined use is authorised).

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

A transient swelling (≤ 5 mm) at the injection site may occur for four to ten days. A transient increase in temperature (< 40.8 °C) may occur while occasionally lethargy for one day after vaccination may be observed.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance.

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI06AD03

To stimulate active immunity against feline rhinotracheitis virus and feline calicivirus.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other vaccine or immunological product except the solvent supplied with the product or with the vaccine in the Nobivac range containing rabies antigen, strain Pasteur RIV (where this product and the combined use is authorised).

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale:

Lyophilisate: 2 years

Solvent: 5 years.

Shelf life after reconstitution according to directions: 30 minutes

5.3 Special precautions for storage

Lyophilisate: Store in a refrigerator (2 °C – 8 °C).

Protect from light.

Solvent: can be stored below 25 °C if stored separately from the lyophilisate.

Do not freeze.

5.4 Nature and composition of immediate packaging

Lyophilisate: 1 dose vial of glass type I (Ph. Eur.) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.

Solvent: 1 dose vial of glass type I (Ph. Eur.) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.

Pack sizes: Cardboard or plastic boxes with 5 x 1 dose, 10 x 1 dose, 25 x 1 dose or 50 x 1 dose of lyophilisate and solvent.

Not all pack-sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Limited
Walton Manor, Walton
Milton Keynes
Buckinghamshire
MK7 7AJ

7. MARKETING AUTHORISATION NUMBER

Vm 01708/3005

8. DATE OF FIRST AUTHORISATION

18 October 2004


9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

March 2023

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).



Approved: 23 March 2023